Atossa Therapeutics, Inc.
ATOS
$1.88
$0.116.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -42.74% | -72.32% | -20.22% | -39.25% | -14.29% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | 0.00% | -20.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 28.24% | -35.35% | -68.10% | 124.86% | 34.37% |
| Change in Net Operating Assets | -473.96% | 92.66% | 10,450.00% | -68.62% | -74.60% |
| Cash from Operations | -60.78% | -49.47% | -26.42% | -60.21% | -26.84% |
| Capital Expenditure | -- | -- | 30.00% | 100.00% | -50.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 30.00% | 100.00% | -50.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -60.54% | -186.42% | -26.30% | -63.71% | -32.62% |